Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh, discussed the design and potential clinical effects of the phase 3 SUPRAME trial (NCT06743126), which is evaluating the efficacy of IMA203, a T-cell receptor–transduced T-cell therapy (TCR-T), vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.
2025
Making Sense of Melanoma Adjuvant Treatment in the Absence of OS Data
We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.
Study reveals a unique vulnerability in melanoma patients with neurofibromin 1 mutations
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.
Resident seeking to better understand primary gastrointestinal melanomas
When most people think of melanoma, they think of skin cancer. If left untreated, melanoma can spread throughout the body.